Macrolide

Animal Antibiotics and Antimicrobials Global Market to Reach $5.26 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 14, 2022
Pharmaceutical, Agriculture, Health, Natural Resources, Mode, Milk, Human, Diet, Asia-Pacific, Poultry, Meat, Acquisition, Bayer, Growth, Partnership, Industry, Egg, Tetracycline antibiotics, Solution, ADM, Research, PETS, Animal, Livestock, Aquaculture, Animal husbandry, Sulfonamide, Cephalosporin, Aminoglycoside, Elanco, Lincosamides, Macrolide, Penicillin, Injection, Quinolone antibiotic

The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Antibiotics and Antimicrobials Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the animal antibiotics and antimicrobials market in 2021.
  • The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market.

Worldwide Legionella Testing Industry to 2027 - Featuring Abbott Laboratories, BioMerieux and Takara Bio Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Health, Biotechnology, Macrolide, Industry, Infection, Tetracycline, Mortality, Doxycycline, COVID-19, Water, Culture, Trimethoprim, Pneumonia, Sputum, Quinolone, Pontiac, Community-acquired pneumonia, Cancer, Antigen, Person-centered therapy, Growth, DFA, Urine, WSP, Kidney disease, Bacteria, HIV, Legislation, Adult, Patient, Polymerase chain reaction, Minocycline, Hospital, PCR, Blood, Pontiac fever, Smoke, Diabetes, Risk, Vaccine, Potash, Legionella

Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms.

Key Points: 
  • Legionella is an infection affecting the lower respiratory tract, which can lead to severe pneumonia, Pontiac fever, and illness with flu-like symptoms.
  • Its testing helps to identify the existence of bacteria or antigens in blood, urine, and sputum.
  • As per the testing results, macrolides, quinolones, tetracycline, doxycycline, minocycline, trimethoprim and other antibiotic treatments are usually administered to patients.
  • What is the structure of the global legionella testing industry and who are the key players?

Outlook on the Macrolide Antibiotics Global Market to 2027 - Focus on Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 12, 2022
Health, Pharmaceutical, Macrolide, Erythromycin, Bacillary angiomatosis, Azithromycin, Skin, Dermatology, Bordetella pertussis, Government, Food and Drug Administration Safety and Innovation Act, Toxoplasmosis, Infection, Taxation of Chargeable Gains Act 1992, Dermatologic Clinics, The Pew Charitable Trusts, Mycoplasma pneumonia, CAGR, Pew, Clarithromycin, Pfizer, Pig, Pharmaceutical industry, Marketing

The global macrolide antibiotics market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global macrolide antibiotics market is anticipated to grow at a considerable CAGR during the forecast period.
  • The global macrolide antibiotics market is segmented based on drugs, route of administration, indication and end-user.
  • Analysis of regional regulations and other government policies impacting the global Macrolide antibiotics market.
  • Insights about market determinants that are stimulating the global macrolide antibiotics market.

The Global Antibiotics Market Will Grow to USD 59,253.24 Million by 2028, at a CAGR of 3.76% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022
Health, General Health, Food and Drug Administration, Bacteria, D, AOM, Economy, Antibiotic sensitivity testing, Development, ASM, Society, Enterobacteriaceae, World, Ill, Geography, Infection, WHO, Bronchitis, Antibiotic, COVID-19, Macrolide, Upper respiratory tract infection, CAGR, Pathogenic bacteria, Pneumonia, Hospital, World Health Organization, Aminoglycoside, Organization, NCBI, Campylobacteriosis, Sulfonamide, 33, Meningitis, Food, Prevalence, Azerbaijan and Organization for Economic Co-operation, Sinusitis, Growth, Death, Diarrhea, Protein, RNA, UNICEF, Genetically modified bacteria, DNA, Poultry, Pharyngitis, Vaccine

The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.

Key Points: 
  • The Antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 3.76% from 2020 to 2028.
  • The growing prevalence of bacterial infection is one of the major factors increasing the demand for antibiotics globally.
  • Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period.
  • Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others.

Global Antibacterial Market Research by Route of Administration, Drug Class, Distribution Channel, Geography, Competitive Analysis - Analysis & Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 20, 2021
Health, Pharmaceutical, CAGR, Genetically modified bacteria, Quinolone, Growth, Geography, Administration, Incidence, Skin, Infection, Route of administration, Bacteria, Climate change and infectious diseases, MDR, Pharmacy, NMPA, Public health, Macrolide, Toxicity, Tablet, Market share, Tetracycline, USD, Vaccine, Pharmaceutical industry

The global antibacterial market is being driven by factors such as increased cases of bacterial infections, changing climatical condition that causes bacterial infection, growing number aged population, and rising demand for efficient and affordable antibacterial Drugs.

Key Points: 
  • The global antibacterial market is being driven by factors such as increased cases of bacterial infections, changing climatical condition that causes bacterial infection, growing number aged population, and rising demand for efficient and affordable antibacterial Drugs.
  • Amongst the two, the enteral segment is estimated to hold the highest market share during the forecast period.
  • By Drug Class, the market is classified as B lactams, quinolones, macrolides, tetracycline, aminoglycoside, sulfonamide, phenicols, others.
  • Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent "Lasvic Tablets 75mg" - 20th September 2019.

EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

Retrieved on: 
Wednesday, August 18, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Company, EIC, Reactive airway disease, Royal commission, Drug development, European Innovation Council, Therapy, Growth, Framework Programmes for Research and Technological Development, Prognosis, ABC, Inflammation, Skin, Macrolide, Infection, Research, Female, Disease, Health, COPD, Time, Fund, Forward-looking statement, Investment, Chronic obstructive pulmonary disease, Multimedia, CDMO, Azithromycin, Senior advisor, Patient, European Commission, CEO, Lung, Degenerative disease, Dermatology, Epithelium, Pharmaceutical industry, Bank, Creative industries, EpiEndo Pharmaceuticals (www.epiendo.com), ABC Ventures, the European Innovation Council Fund (eic.ec.europa.eu), Flerie Invest (www.flerie.com), Iðunn Venture Fund (www.kvikaeignastyring.is/en), EPIENDO PHARMACEUTICALS (WWW.EPIENDO.COM), ABC VENTURES, THE EUROPEAN INNOVATION COUNCIL FUND (EIC.EC.EUROPA.EU), FLERIE INVEST (WWW.FLERIE.COM), IðUNN VENTURE FUND (WWW.KVIKAEIGNASTYRING.IS/EN)

The financing secures funds to advance clinical development of EpiEndos lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.

Key Points: 
  • The financing secures funds to advance clinical development of EpiEndos lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
  • Using this Series A funding, EpiEndo aims to advance the clinical development of EP395 towards approval as the first disease modifying non-antibiotic macrolide that can be prescribed safely and effectively as a long-term treatment for patients with COPD.
  • We have followed EpiEndo for some time and have seen impressive progress towards clinical phase of their lead compound EP 395.
  • EpiEndos lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.

Global Animal Antibiotics and Antimicrobials Industry (2020 to 2027) - Key Market Trends and Drivers - ResearchAndMarkets.com

Retrieved on: 
Monday, August 16, 2021
Pharmaceutical, Health, Pets, Consumer, Tetracycline, CAGR, COVID-19, Antimicrobial, Penicillin, Growth, Macrolide, Pet

The "Animal Antibiotics and Antimicrobials - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Antibiotics and Antimicrobials - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Tetracycline, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$1.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 7.4% CAGR
    The Animal Antibiotics and Antimicrobials market in the U.S. is estimated at US$1.2 Billion in the year 2020.
  • In the global Macrolide segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment.

Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines

Retrieved on: 
Tuesday, February 23, 2021
Bacteria, Pneumonia, Medical specialties, Infectious diseases, Microbiology, Pathogenic bacteria, Polysaccharide encapsulated bacteria, Macrolide, Community-acquired pneumonia, Streptococcus pneumoniae

Macrolide resistance was observed in 47.3 percent of S. pneumoniae obtained from respiratory cultures, and 29.6 percent from blood cultures.

Key Points: 
  • Macrolide resistance was observed in 47.3 percent of S. pneumoniae obtained from respiratory cultures, and 29.6 percent from blood cultures.
  • In addition, higher rates of macrolide resistance were seen among ambulatory patients (45.3 percent) as compared with inpatients (37.8 percent).
  • Macrolide-resistant S. pneumoniae is designated as a serious public health threat according to the Centers for Disease Control and Prevention (CDC).
  • Based on current treatment guidelines, clinicians should consider alternatives to macrolide monotherapy for community-acquired pneumonia in the U.S.

Everest Medicines Announces Positive Results of In Vitro Study of Xerava™ (eravacycline) Against Human Mycoplasmas

Retrieved on: 
Tuesday, June 23, 2020
Sexually transmitted diseases and infections, Medical specialties, Bacterial vaginosis, Antimicrobial, Biocides, Macrolide, Antibiotic, Medicine, Mycoplasma, Human reproduction

These results suggest Xerava merits further clinical study as a potential therapeutic option to macrolides and existing antibiotics for the treatment of some respiratory infections caused by human mycoplasmas.

Key Points: 
  • These results suggest Xerava merits further clinical study as a potential therapeutic option to macrolides and existing antibiotics for the treatment of some respiratory infections caused by human mycoplasmas.
  • Findings from the study are published in the June 2020 journal issue of Antimicrobial Agents and Chemotherapy (AAC).
  • The paper, entitled In Vitro Activities of Eravacycline and Other Antimicrobial Agents Against Human Mycoplasmas and Ureaplasmas is available online here .
  • Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development.

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Retrieved on: 
Monday, May 18, 2020
Bacteria, Medical specialties, Branches of biology, Pneumonia, Pathogenic bacteria, Polysaccharide encapsulated bacteria, Infectious diseases, Streptococcaceae, Streptococcus pneumoniae, Macrolide, Medical microbiology, Klebsiella pneumoniae

Prevalence and Regional Variation in Macrolide Resistant S. pneumoniae from Blood or Respiratory Cultures among Adult Patients (Abstract #5523), online in the proceedings of 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID).

Key Points: 
  • Prevalence and Regional Variation in Macrolide Resistant S. pneumoniae from Blood or Respiratory Cultures among Adult Patients (Abstract #5523), online in the proceedings of 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID).
  • Macrolide resistance was observed in 47.3 percent of S. pneumoniae obtained from respiratory cultures, and 29.6 percent from blood cultures.
  • In its 2019 Antibiotic Threats Report, the Centers for Disease Control and Prevention (CDC) designated macrolide-resistant S. pneumoniae as a Serious Threat to patients.
  • XENLETA has a novel mechanism of action that targets a binding site on bacteria that is different from existing antibiotics.